GlobeNewswire

Striving for Gold - Laying the Groundwork for the Olympic Healthcare Interoperability Initiative

Dela

LAS VEGAS, Nev., March 06, 2018 (GLOBE NEWSWIRE) -- The spirit of health and well-being is core to the founding principles of the Olympic Games and heralds the tenets of sustainable social development within each host and participating country. With the ambitious goal of integrating advanced digital health information sharing into health services provided before, during, and after the Games, the Olympic Healthcare Interoperability (OHI) Initiative & OHI Foundation have been formed to aggressively pursue this vision.

OHI, a digital health industry initiative with charter sponsorship from not-for-profit organizations HIMSS and SNOMED International, was created to advance the seamless exchange and use of health information globally through the Olympic Games. Starting with the 2020 Summer Games in Tokyo, OHI's goal is to "showcase the possible" and "implement the real", through the communication of digital health information, for the benefit of the 1,000's of athletes, trainers and staff, volunteers and attendees. With each edition of the Games, a digital health legacy will be crafted to establish a comprehensive, world-wide infrastructure supportive of appropriate access to relevant clinical information...anywhere, at any time.

Utilizing the latest innovations in digital health, OHI will connect pre-Games, person-specific healthcare information with information generated at the Games by Olympic and Host City healthcare service providers, which will flow back around the world with each individual once the Games conclude. OHI's initial scope will include patient identity matching and access to international patient summaries with capacity to include the significant facets of a patient's digital health record over time.  All with the needed security, privacy and consent framework that will ensure appropriate access to all information.

Consider the case of a Jamaican athlete collapsing on the track, showing symptoms of cardiac stress.  Medical personnel at the stadium use an electronic medical record (EMR) system to query the athlete's electronic records from Jamaica, and discover a number of allergies, current medications, and medical conditions to inform a treatment plan. The athlete, requiring a surgical procedure and transferred to the host city's tertiary hospital, is followed by the necessary diagnostic and treatment information via OHI interoperability.  Post surgery, the updated medical record is posted to the athlete's Jamaican EMR system for follow-up medical treatment at home.

As a way to build an Olympic digital health ecosystem that includes all stakeholders willing to specify, prototype and deploy digital health technology, the OHI Foundation has been created as a not-for-profit, charitable organization.  The Foundation itself has no restriction on membership, and welcomes the participation and support of the global digital health community, namely vendors, healthcare providers, industry and standards organizations.

Recognized charter supporters, HIMSS and SNOMED International, lend their commitment to the pursuit of quality and safety improvements through health information technology and standards alike. Hal Wolfe, HIMSS CEO, states that "HIMSS is proud to sponsor the OHI Initiative as a representative of the digital health industry globally.  OHI supports an ecosystem at the Olympic Games that is built on the same standards, products and infrastructures that are being implemented around the world in order to deliver better health through information and technology. our industry is dedicated to the realization of that vision." Don Sweete, CEO, SNOMED International,  echoes that sentiment. "At the core of care delivery is the principle that clinicians can, beyond a shadow of a doubt, rely on available, accessible and unambiguous clinical information at any point of service. Demonstrating this critical relationship at work through OHI and in support of the healthcare program offered at each Olympic Games, we see a forward-looking example made possible by the interoperability of health information."

Michael Nusbaum, OHI's Executive Lead, has been a driving force in realizing the OHI vision. "Launching OHI through this year's HIMSS18 Interoperability Showcase speaks to the promise of global healthcare interoperability delivered through the lens of the Olympic Games, and for the benefit of participants, national teams, and host countries."

Interested parties can learn more about this initiative at a presentation and drinks reception Tuesday March 6, 4:30pm - 5:30pm  at the HIMSS Interoperability Showcase Theatre, and at an educational session Wednesday March 7th, 1:00pm - 2:00pm in Murano 3301.  Organizations and individuals interested in becoming an OHI Foundation partner are invited to visit the OHI kiosk at the Interoperability Showcase.

About OHI:
OHI, the Olympic Healthcare Interoperability Initiative, began early in 2017 to advance the seamless exchange and use of health information globally, leveraging the 2-year cadence of the Olympic Games and established international standards. Utilizing the latest innovations in digital health, OHI will connect pre-Games person-specific healthcare information with information generated at Games time by Olympic and Host City healthcare service providers: from athletes to staff/officials to volunteers to spectators.

The OHI Foundation is a not-for-profit, charitable organization based in the U.S. The Foundation provides the facilitation and management services required to progress its vision of advancing the use of digital health technology in conjunction with the Olympic Games to impact the health of individuals around the world. 

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0abf3f67-1fe7-43ac-ba17-1a58759b3431

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/49164c85-434e-4f60-bb85-d2ecdf2282de

Michael Nusbaum
Olympic Healthcare Interoperability Initiative 
+1 (250) 384-0001
michael@ohiinitiative.org



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Olympic Healthcare Interoperability Initiative via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum